Search Results
Results found for "Yulong Li"
- Structure of Mycobacterium tuberculosis Cya, an evolutionary ancestor of the mammalian membrane...
domain and providing the means for direct regulation of catalytic activity in response to extracellular ligands
- Multifunctional role of GPCR signaling in epithelial tube formation
During Drosophila embryonic salivary gland (SG) invagination, the GPCR ligand Folded gastrulation (Fog Our data support a model wherein Smog regulates distinct myosin pools and actin cytoskeleton in a ligand-dependent
- Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus
nucleus accumbens shell and structures in the prefrontal cortex and amygdala, which were previously linked
- Endothelin-1 Stimulates PAI-1 Protein Expression via Dual Transactivation Pathway Dependent ROCK...
Smad2L "In addition to the carboxy region, Smad2 transcription factor can be phosphorylated in the linker Phosphorylation of Smad2 linker region (Smad2L) promotes the expression of plasminogen activator inhibitor were investigated<br />by western blotting using protein-specific antibodies against phospho-Smad2 linker
- Lack of Oestrogen Receptor Expression in Breast Cancer Cells Does Not Correlate with Kisspeptin...
KISS1R signalling and physiological output in the hormone receptor-negative MDA-MB-231 and BT-20 cell lines MDA-MB-231 cells are metastatic when implanted in mice while BT-20 are not and remain epithelial-like We show that both cell lines express KISS1R mRNA and respond to KP-10 by elevating calcium mobilisation Interestingly, both cell lines displayed different complements of β-arrestin 1 and 2 expression. stimulate migration or pro-metastatic behaviour, as divergent responses were observed in the two TNBC lines
- Delineation of GPR15 receptor-mediated Gα protein signaling profile in recombinant mammalian cell
receptor-mediated Gα protein signalling using a G protein activation assay and second messenger assay conducted on living
- Microbial Metabolites Orchestrate a Distinct Multi-Tiered Regulatory Network in the Intestinal Epith
Using shRNA knockdown and CRISPR/Cas9 knockout cell lines, as well as mouse models, we confirmed the These findings shed light on a sophisticated signaling network directed by intestinal microbial metabolites that orchestrate P-gp expression and highlight unappreciated connections between multiple pathways linked
- Pharmacological Properties and Function of PxOctβ3 Octopamine Receptor in Plutella xylostella (L.)
Thus, we investigated the regulatory functions of its β-adrenergic-like octopamine receptor (PxOctβ3)
- GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...
Mechanistically, GASP1 inhibited proteasomal degradation of insulin-like growth factor 1 receptor (IGF1R ) by competitively binding to IGF1R with ubiquitin E3 ligase MDM2, thereby activating its downstream
- To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from...
While the receptor with the crystal ligand (i.e. antagonist naltrindole) maintained the inactive conformation the conventional molecular switch analysis and a pairwise distance analysis, which provides a short list
- Structural basis for receptor selectivity and inverse agonism in S1P5 receptors
The structure demonstrates a unique ligand-binding mode, involving an allosteric sub-pocket, which clarifies structures in complex with antagonists and agonists, our structure with S1P5-inverse agonist sheds light
- Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify...
Additionally, we employed optical assays in living cells to thoroughly profile both GPR35 isoforms for constitutive and ligand-induced activation and signaling of 10 different heterotrimeric G proteins, ligand-induced arrestin recruitment, and receptor internalization. Our results reveal that the extended N-terminus of the long isoform limits G protein activation yet elevates and mechanistic insights of our study provide clues for the future design of isoform-specific GPR35 ligands
- Trainees, this is for you...
Would you like to develop your presentation skills? Give a talk or present a poster at the Dr.
- Carola Weiss joins InterAx Biotech AG as VP Business Development
Carola Weiss’ professional career brings deep expertise in business development, marketing & sales, licensing
- Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline ...
England & BOSTON--Sanofi and Exscientia announced today a groundbreaking research collaboration and license The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel
- Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...
DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced positive top-line
- ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated ...
receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein
- Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1
Erythrocytes are terminally differentiated anuclear cells with no transcription and limited translation Accordingly, within the erythroid lineage ACKR1 expression occurs first and is the highest in erythroblasts venular endothelial cells (ECs) ( Pruenster et al., 2009 ; Thiriot et al., 2017 ), including those lining macrophages, but not erythroblasts and ECs, suggesting that macrophage ACKR1 engages its non-cognate ligand In light of the extensive literature, these findings have been particularly provocative, as this was
- 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry. October 5-7, 2022, Verona, Italy
Wednesday-Friday, 5th-7th October 2022 Place Evotec Campus Levi-Montalcini, Verona, Italy Downloads and Links
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living
- 4GPCRnet, September 26-29, 2022. Leipzig, Germany
will take place in the heart of Leipzig, which offers a colorful mixture of culture and vivid social life
- Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists
It is a therapeutic target because it plays a role in thermogenesis, lipolysis, and bladder relaxation Ligand-based pharmacophore modeling was performed since no 3D structure of human β3 -AR is yet available
- Crinetics Presents Clinical And Research Results At ENDO 2022
serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
discovery involving the gut-brain axis, will gain unique and valuable access to the Sosei Heptares compound library
- Targeting the M1 muscarinic receptor in neurodegenerative disease
cognitive and neurodegenerative disorders and the potential therapeutic benefit of muscarinic M1 selective ligands
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences
- Domain Therapeutics Raises $42m Series A Financing
announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
structure-based drug design platform and enhancing translational medicine capabilities • ‘Venture-like value generation • Mid-term global expansion plans include drug discovery technology investments, licensing

